Efforts to minimize oral contraceptive side effects have focused on the use of new dosage
schemes and the synthesis of new steroids that can be used in safer, low-dose formulations …

The minimal effective dose of gestodene for inhibition of ovulation was studied in 30 female
volunteers. Daily doses of 10 μg to 50 μg gestodene were given orally for 21 days. A control …

The newer progestogens gestodene, desogestrel and norgestimate were developed in an
attempt to produce agents with more selective progestational activity that would improve …

Ovulation inhibition by the monophasic oral contraceptive containing 75 μg of gestodene
and 30 wg of ethinyl estradiol was evaluated in 25 healthy volunteers for five cycles: a …

The pharmacokinetic and protein-binding properties of gestodene and ethinyl estradiol have
been investigated after single and multiple dosing in several studies in 83 healthy, young …

The new low-dose combination oral contraceptive (OC) containing 75 micrograms of the
new progestogen gestodene (GTD) plus 30 micrograms ethinyl estradiol (EE) was clinically …

Twenty-five healthy women volunteers were selected to evaluate ovulation inhibition by a
monophasic oral contraceptive preparation containing 75 micrograms gestodene and 30 …

An open label, non-comparative study was carried out in 22 women over a total of five
cycles. After an untreated cycle, oral administration of 20 μg ethinyl estradiol (EE) with 50 μg …

Abstract Gestodene, 17α-ethinyl-13-ethyl-17β-hydroxy-4, 15-gonadien-3-one, is a new
orally active progestational agent, which is available for clinical use in oral contraceptives …

The monophasic combination preparation containing 30 micrograms ethinyl estradiol and
75 micrograms gestodene was tested for contraceptive reliability, cycle control and …